Posted by Michael Wonder on 13 Aug 2020
Elusys Therapeutics receives Health Canada approval for Anthim for the treatment of inhalation anthrax
12 August 2020 - Elusys Therapeutics today announced that Health Canada has approved the company's new drug submission for Anthim (obiltoxaximab for injection), the company's monoclonal antibody anthrax antitoxin for the treatment of inhalation anthrax.
Anthim is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate anti-bacterial drugs; and for post-exposure prophylaxis of inhalational anthrax due to B. anthracis when alternative therapies are not available or not appropriate.
Anthim was approved under the Extraordinary Use New Drug Regulations, leveraging data from previous studies funded by U.S. government agencies, including the Biomedical Advanced Research and Development Authority, the National Institutes of Health, and the U.S. Department of Defense.
